Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...

Antihypertensive Drugs: Direct Renin Inhibitors

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...

Hormonal Regulation

Hormonal Regulation

The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.

Antihypertensive Drugs: Angiotensin II Receptor Blockers

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...

TGF - β Signaling Pathway

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Antibiotic resistance genes in surface water of eutrophic urban lakes are related to heavy metals, antibiotics, lake morphology and anthropic impact.

Ecotoxicology (London, England)·2017

Same author

HER2 assessment in locally advanced gastric cancer: comparing the results obtained with the use of two primary tumour blocks versus those obtained with the use of all primary tumour blocks.

Histopathology·2017

Same author

Inflammatory microRNA-194 and -515 attenuate the biosynthesis of chondroitin sulfate during human intervertebral disc degeneration.

Oncotarget·2017

Same author

Soil Acidification Aggravates the Occurrence of Bacterial Wilt in South China.

Frontiers in microbiology·2017

Same author

Is the Prophylactic Use of Hepatoprotectants Necessary in Anti-Tuberculosis Treatment?

Chemotherapy·2017

Same author

Light-induced aggregation of microbial exopolymeric substances.

Chemosphere·2017

Search research articles

Related Experiment Videos

Aldosterone and TGF-beta1 synergistically increase PAI-1 and decrease matrix degradation in rat renal mesangial and

Wei Huang¹, Chen Xu, Kyoung W Kahng

¹Fibrosis Research Laboratory, Division of Nephrology, University of Utah School of Medicine, Salt Lake City, UT 84108, USA.

American Journal of Physiology. Renal Physiology

|March 28, 2008

Summary

Aldosterone increases renal fibrosis by boosting plasminogen activator inhibitor type 1 (PAI-1), partly via TGF-beta. Combined aldosterone and TGF-beta synergistically increase PAI-1 and reduce extracellular matrix degradation.

Related Experiment Videos

Area of Science:

Nephrology
Endocrinology
Cell Biology

Background:

Aldosterone is implicated in renal fibrosis, potentially through regulating plasminogen activator inhibitor type 1 (PAI-1).
PAI-1 is a key inhibitor of extracellular matrix (ECM) degradation, a process central to fibrosis.

Purpose of the Study:

To investigate aldosterone's effects on PAI-1 and transforming growth factor-beta (TGF-beta) in kidney cells.
To determine if PAI-1's actions are TGF-beta mediated.
To assess synergistic effects of aldosterone and TGF-beta on PAI-1 production and ECM degradation.

Main Methods:

Cultured rat mesangial cells (MCs) and normal rat kidney (NRK)-49F fibroblasts.
Measured ECM degradation by quantifying release of 3H-labeled ECM.
Assessed PAI-1 mRNA and protein levels following aldosterone and/or TGF-beta treatment.

Main Results:

Aldosterone significantly increased PAI-1 mRNA and protein in both MCs and NRK-49F cells.
These increases were blocked by spironolactone and partially by TGF-beta neutralizing antibody.
Co-administration of aldosterone and TGF-beta(1) resulted in synergistic increases in PAI-1 and marked inhibition of ECM degradation.

Conclusions:

Aldosterone-induced PAI-1 elevation is partially mediated by TGF-beta(1).
Aldosterone and TGF-beta(1) act synergistically to enhance PAI-1 production and inhibit ECM degradation.
Elevated aldosterone may amplify profibrotic actions of the renin-angiotensin-aldosterone system.